Table 7 Multivariate analysis to demonstrate genotype interaction of studied SNPs (based on their cellular functions) and influence of anti-VEGF treatment on AMD pathology. Results showed significant genotype interaction of pro-angiogenic genes including ADAMTS9 (rs6795735) and TIMP3 (rs5749482), but didn’t show direct influence of genotype interactions on number of anti-VEGF injections in Indian AMD patients.
Multivariate tests | |||||||
---|---|---|---|---|---|---|---|
Genotype interactions | Effect | Test | Value | F | Hypothesis df | Error df | P-value |
B3GALTL (rs9542236) * LIPC (rs920915) | Intercept | Pillai's Trace | .342 | 9.875 | 2 | 38 | < 0.0001 |
Anti-VEGF number | Pillai's Trace | .056 | 1.137 | 2 | 38 | .331 | |
B3GALTL genotype | Pillai's Trace | .011 | .103 | 4 | 78 | .981 | |
LIPC genotype | Pillai's Trace | .475 | 6.078 | 4 | 78 | < 0.0001 | |
B3GALTL * LIPC genotype | Pillai's Trace | .051 | 1.014 | 2 | 38 | .372 | |
APOE (rs769449) * HTRA1 (rs11200638) | Intercept | Wilks' Lambda | .260 | 58.273 | 2 | 41 | < 0.0001 |
Anti-VEGF number | Wilks' Lambda | .943 | 1.246 | 2 | 41 | .298 | |
APOE genotype | Wilks' Lambda | .810 | 4.795 | 2 | 41 | .013 | |
HTRA1 genotype | Wilks' Lambda | .781 | 2.695 | 4 | 82 | .036 | |
APOE * HTRA1 | Wilks' Lambda | .835 | 1.938 | 4 | 82 | .112 | |
Pro-angiogenic genotype interaction ADAMTS9 (rs6795735) * TIMP3 (rs5749482) | Intercept | Pillai's Trace | .698 | 46.138 | 2 | 40 | < 0.0001 |
Anti-VEGF number | Pillai's Trace | .006 | .127 | 2 | 40 | .881 | |
ADAMTS9 Genotype | Pillai's Trace | .408 | 5.260 | 4 | 82 | .001 | |
TIMP3 genotype | Pillai's Trace | .370 | 11.751 | 2 | 40 | < 0.0001 | |
ADAMTS9 * TIMP3 genotype | Pillai's Trace | .480 | 6.466 | 4 | 82 | < 0.0001 | |
Regulatory genotype interaction HTRA1 (rs11200638) * IER3 (rs3130783) | Intercept | Pillai's Trace | .189 | 4.090 | 2 | 35 | .025 |
Anti-VEGF number | Pillai's Trace | .035 | .640 | 2 | 35 | .533 | |
HTRA1 genotype | Pillai's Trace | .071 | .666 | 4 | 72 | .618 | |
IER3 genotype | Pillai's Trace | .002 | .028 | 2 | 35 | .972 | |
HTRA1 * IER3 genotype | Pillai's Trace | .033 | .596 | 2 | 35 | .557 | |
Cellular function SLC16A8 (rs8135665) * B3GALTL (rs9542236) | Intercept | Pillai's Trace | .100 | 2.271 | 2 | 41 | .116 |
Anti-VEGF number | Pillai's Trace | .008 | .175 | 2 | 41 | .840 | |
SLC16A8 genotype | Pillai's Trace | .091 | .998 | 4 | 84 | .413 | |
B3GALTL | Pillai's Trace | .086 | .941 | 4 | 84 | .445 | |
SLC16A8 * B3GALTL | Pillai's Trace | .007 | .146 | 2 | 41 | .864 | |
Lipid metabolizing APOE (rs769449) * LIPC (rs920915) | Intercept | Pillai's Trace | .324 | 8.871 | 2 | 37 | .001 |
Anti-VEGF number | Pillai's Trace | .013 | .249 | 2 | 37 | .781 | |
APOE genotype | Pillai's Trace | .006 | .112 | 2 | 37 | .895 | |
LIPC genotype | Pillai's Trace | .057 | .553 | 4 | 76 | .697 | |
APOE * LIPC | Pillai's Trace | .078 | 1.575 | 2 | 37 | .221 |